Transcatheter Tricuspid Valve Replacement Using the Lux-Valve Plus System

Inclusion Criteria: * Patients aged 50- to 90-year-old * Severe symptomatic tricuspid regurgitation (NYHA III-IV) despite optimal medical therapy * Deem high risk for tricuspid valve surgery determined by a multidisciplinary heart team (including cardiologists, cardiac surgeons and cardiac anesthetists) * Anatomically not feasible with other transcatheter tricuspid valve therapy that is commercially available in Hong Kong (i.e. TriClip System) * Capacity to provide informed consent Exclusion Criteria: * Systolic pulmonary artery pressure (sPAP) \> 60 mmHg assessed by echocardiography * Left Ventricular Ejection Fraction (LVEF) \<40% * Evidence of intracardiac mass, thrombus or vegetation * Anatomical structures precluding proper device deployment or device vascular access, evaluated by echo or CT * Surgical correction is indicated for other concomitant valvular disease (e.g., severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation); Subjects with concomitant valvular disease may treat their respective valve first and wait 2 months before being reassessed for the trial. * Sepsis or active endocarditis within 3 months, or infections requiring antibiotic therapy within 2 weeks prior to the planned procedure * Active peptic ulcer or active gastrointestinal (GI) bleeding precluding anticoagulation or antiplatelet therapy * Subjects currently participating in another clinical trial of an investigational drug or device that has not yet completed its primary endpoint.